Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.
about
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunityAnthrax vaccination strategiesHigh-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ.Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entitiesAn anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.Immunization of Mice with Anthrax Protective Antigen Limits Cardiotoxicity but Not Hepatotoxicity Following Lethal Toxin ChallengePast, imminent and future human medical countermeasures for anthrax.Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralizationRecombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen.The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
P2860
Q28383065-622CC6E3-4931-479E-B71C-098FF981321AQ28392248-0B386A38-1F2D-4065-8A74-33C4BB0857D2Q33285349-DA64F0F5-BC19-4F9C-9735-AB5AA96B6204Q33769076-6CF8B274-7B83-4162-9AF2-188B8EB210F0Q33936452-332A2F1F-F927-4462-B0A1-7CA1D797AFFEQ34000070-C0B85804-5EC0-4B38-B5AB-97CA0BC7BD6DQ34241550-8FFF9C81-149C-46E9-AF95-C0675C89E083Q34433313-0307699D-7D55-414F-BE69-8CD2F6401419Q35894690-F801724F-AE92-49C5-8378-6A7527006017Q36565152-AE179907-BB43-45F6-9695-49B9060173BFQ36733960-B116A7B3-3F21-4CB4-BE7C-CE69D040EC07Q36980383-75D5D9F0-5197-4554-BCD1-DDA55AABC738Q37451219-E36E8F16-BDEC-4FFD-9D22-EF1C15F26D75Q39205816-32E69BEF-281D-484D-84FF-D62DC23CDC48
P2860
Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Protective antigen and toxin n ...... dergoing serial plasmapheresis
@nl
Protective antigen and toxin n ...... ergoing serial plasmapheresis.
@ast
Protective antigen and toxin n ...... ergoing serial plasmapheresis.
@en
type
label
Protective antigen and toxin n ...... dergoing serial plasmapheresis
@nl
Protective antigen and toxin n ...... ergoing serial plasmapheresis.
@ast
Protective antigen and toxin n ...... ergoing serial plasmapheresis.
@en
prefLabel
Protective antigen and toxin n ...... dergoing serial plasmapheresis
@nl
Protective antigen and toxin n ...... ergoing serial plasmapheresis.
@ast
Protective antigen and toxin n ...... ergoing serial plasmapheresis.
@en
P2093
P2860
P1476
Protective antigen and toxin n ...... dergoing serial plasmapheresis
@en
P2093
Bonnie S Sink
Julio G Barrera Oro
Kelly T McKee
Manmohan V Ranadive
Nina M Marano
Sarah L Norris
Susan F Leitman
P2860
P304
P356
10.1128/CDLI.12.6.713-721.2005
P407
P50
P577
2005-06-01T00:00:00Z